Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IKZPQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
B12-PEG-G4-DOX
|
|||||
| Synonyms |
B12-PEG-G4 DOX
Click to Show/Hide
|
|||||
| Organization |
Abion, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
14
|
|||||
| Antibody Name |
B12
|
Antibody Info | ||||
| Antigen Name |
Envelope glycoprotein gp160 (env)
|
Antigen Info | ||||
| Payload Name |
Cis-aconityl-doxorubicin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
B12-PEG-G4-DOX linker
|
|||||
| Conjugate Type |
Random conjugation through reduced heavy-chain cysteines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.